See more : SMIFS Capital Markets Limited (SMIFS.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Nabriva Therapeutics plc (NBRV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nabriva Therapeutics plc, a leading company in the Biotechnology industry within the Healthcare sector.
- NTT Data Intramart Corporation (3850.T) Income Statement Analysis – Financial Results
- 52 Weeks Entertainment Limited (SHAQUAK.BO) Income Statement Analysis – Financial Results
- Jiangsu Huachang Chemical Co., Ltd. (002274.SZ) Income Statement Analysis – Financial Results
- PHAXIAM Therapeutics S.A. (PHXM.PA) Income Statement Analysis – Financial Results
- Future Labs V, Inc. (GRAZ) Income Statement Analysis – Financial Results
Nabriva Therapeutics plc (NBRV)
About Nabriva Therapeutics plc
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 35.67M | 27.22M | 2.86M | 7.75M | 6.50M | 0.00 | 0.00 | 84.00K | 0.00 | 0.00 |
| Cost of Revenue | 28.58M | 13.15M | 766.00K | 70.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 7.09M | 14.07M | 2.10M | 7.68M | 6.50M | 0.00 | 0.00 | 84.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 19.87% | 51.69% | 73.25% | 99.10% | 100.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 14.26M | 12.63M | 15.10M | 26.42M | 82.29M | 49.62M | 47.99M | 22.73M | 8.59M | 10.11M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 41.74M | 29.47M | 13.44M | 7.82M | 3.46M | 3.91M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 45.26M | 51.65M | 55.29M | 62.49M | 41.74M | 29.47M | 13.44M | 7.82M | 3.46M | 3.91M |
| Other Expenses | -1.27M | -1.68M | -2.16M | -1.73M | -272.00K | 492.00K | 55.00K | 2.86M | 77.82K | 34.30M |
| Operating Expenses | 58.26M | 62.60M | 68.22M | 87.17M | 120.88M | 73.77M | 55.05M | 26.84M | 9.89M | 6.74M |
| Cost & Expenses | 86.84M | 75.74M | 68.99M | 87.24M | 120.88M | 73.77M | 55.05M | 26.84M | 9.89M | 6.74M |
| Interest Income | 0.00 | 0.00 | 86.00K | 255.00K | 49.00K | 318.00K | 343.00K | 6.74M | 2.43K | 307.93K |
| Interest Expense | 698.00K | 0.00 | 1.74M | 3.64M | 133.00K | 43.00K | 75.00K | 14.59M | 6.98M | 5.55M |
| Depreciation & Amortization | -3.53M | 637.00K | 1.27M | 470.00K | 510.00K | 432.00K | 233.00K | 150.88K | 152.00K | 197.46K |
| EBITDA | -54.70M | -48.53M | -64.85M | -79.02M | -114.09M | -72.53M | -54.42M | -17.24M | -9.75M | 28.06M |
| EBITDA Ratio | -153.36% | -178.31% | -2,264.42% | -1,019.86% | -1,755.20% | 0.00% | 0.00% | -20,518.94% | 0.00% | 0.00% |
| Operating Income | -51.17M | -48.53M | -66.13M | -79.49M | -114.38M | -73.77M | -55.05M | -23.98M | -9.77M | 22.31M |
| Operating Income Ratio | -143.47% | -178.31% | -2,308.87% | -1,025.93% | -1,759.62% | 0.00% | 0.00% | -28,544.30% | 0.00% | 0.00% |
| Total Other Income/Expenses | -4.44M | -432.00K | -3.22M | -3.17M | -356.00K | 767.00K | -515.00K | 2.86M | -6.42M | -5.76M |
| Income Before Tax | -55.62M | -48.96M | -69.35M | -82.66M | -114.73M | -73.00M | -55.56M | -31.82M | -16.18M | 16.55M |
| Income Before Tax Ratio | -155.93% | -179.89% | -2,421.26% | -1,066.89% | -1,765.09% | 0.00% | 0.00% | -37,886.83% | 0.00% | 0.00% |
| Income Tax Expense | 1.57M | 490.00K | 139.00K | 101.00K | 49.00K | 1.36M | -672.00K | -438.41K | 87.55K | 1.07M |
| Net Income | -57.19M | -49.45M | -69.48M | -82.76M | -114.78M | -74.36M | -54.89M | -31.39M | -16.27M | 15.48M |
| Net Income Ratio | -160.33% | -181.69% | -2,426.12% | -1,068.20% | -1,765.85% | 0.00% | 0.00% | -37,364.91% | 0.00% | 0.00% |
| EPS | -21.32 | -28.52 | -135.23 | -278.86 | -564.91 | -623.15 | -638.90 | -741.38 | -149.52 | 142.25 |
| EPS Diluted | -21.32 | -28.52 | -135.23 | -278.86 | -564.91 | -623.15 | -638.90 | -741.38 | -149.52 | 130.92 |
| Weighted Avg Shares Out | 2.68M | 1.73M | 513.80K | 296.80K | 203.18K | 119.32K | 85.91K | 42.34K | 108.82K | 108.82K |
| Weighted Avg Shares Out (Dil) | 2.68M | 1.73M | 513.80K | 296.80K | 203.18K | 119.32K | 85.91K | 42.34K | 108.82K | 108.82K |
Nabriva Therapeutics to Present at the Jefferies Virtual Healthcare Conference
Nabriva Therapeutics plc (NBRV) CEO Ted Schroeder on Q1 2021 Results - Earnings Call Transcript
Nabriva Therapeutics to Report First Quarter 2021 Financial Results and Recent Corporate Highlights on May 6, 2021
Rising P/E: An Overlooked Way to Pick 5 Winning Stocks
Nabriva Commences Exclusive Distribution of SIVEXTRO® (tedizolid phosphate) in the U.S.
Rising P/E: An Overlooked Strategy to Pick Winning Stocks
5 Best Stocks With Rising P/E to Buy for Solid Returns
Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nabriva Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
NBRV Stock Price Increases Over 15% Pre-Market: Why It Happened
Source: https://incomestatements.info
Category: Stock Reports